Medpace (NASDAQ:MEDP) Stock Price Up 6.7% After Strong Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP)’s stock price was up 6.7% on Wednesday following a stronger than expected earnings report. The company traded as high as $661.99 and last traded at $664.0180. 256,301 shares traded hands during mid-day trading, a decline of 21% from the average daily volume of 326,005 shares. The stock had previously closed at $622.43.

The company reported $4.84 EPS for the quarter, topping the consensus estimate of $4.44 by $0.40. The company had revenue of $716.00 million during the quarter, compared to analyst estimates of $714.47 million. Medpace had a return on equity of 104.17% and a net margin of 18.24%. Medpace’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.86 earnings per share.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Third-quarter results exceeded expectations. Medpace reported adjusted earnings of $4.84 per share, ahead of the roughly $4.44-$4.45 consensus, while revenue reached $716 million versus estimates of $714.5 million. Revenue increased 8.5% year over year, and earnings rose from $3.86 per share in the prior-year quarter. Medpace Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Forward outlook and demand indicators supported the bullish case. Management forecast 2026 earnings of $17.97-$18.32 per share, described as above Wall Street expectations. Net new business awards totaled $873 million in the quarter, and ending backlog rose 5.6% year over year to $3.2 billion, providing revenue visibility. Medpace 2026 Forecast and Buyback
• Positive Sentiment: A new $1 billion buyback may bolster shareholder returns. The authorization replaces the prior repurchase program and signals management’s confidence in cash generation and the company’s valuation, while reducing the number of shares outstanding if fully executed. Medpace Buyback and Third-Quarter Profit
• Neutral Sentiment: Analyst sentiment remains cautious. Deutsche Bank raised its price target to $650 from $535 but maintained a Hold rating, suggesting improved expectations are already largely reflected in the shares. Deutsche Bank Medpace Price Target
• Negative Sentiment: Valuation and growth concerns limited the reaction. Commentary characterized MEDP as potentially about 24% overvalued, while the stock’s elevated earnings multiple leaves less room for execution or guidance disappointments. Investors also questioned whether the modest backlog growth and revenue expansion were sufficient to justify the premium valuation. Medpace Valuation After Q3 Beat

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Barclays set a $675.00 price target on shares of Medpace in a research report on Friday. Truist Financial raised their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Royal Bank Of Canada boosted their target price on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Weiss Ratings raised shares of Medpace from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Finally, TD Cowen upped their target price on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $612.27.

Insiders Place Their Bets

In other Medpace news, CEO August Troendle sold 49,018 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the completion of the sale, the chief executive officer owned 433,372 shares of the company’s stock, valued at approximately $272,205,286.92. The trade was a 10.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 336,140 shares of company stock worth $208,008,328 in the last quarter. 20.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Johnson Financial Group Inc. bought a new position in shares of Medpace during the 2nd quarter valued at approximately $27,000. Jones Financial Companies Lllp purchased a new stake in Medpace in the 2nd quarter worth approximately $30,000. Allied Private Wealth LLC purchased a new stake in Medpace in the 2nd quarter worth approximately $31,000. Kilter Group LLC purchased a new stake in Medpace in the 2nd quarter worth approximately $31,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Medpace during the 2nd quarter worth approximately $34,000. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 1.3%

The company has a market cap of $18.25 billion, a P/E ratio of 38.33, a PEG ratio of 2.96 and a beta of 1.18. The business’s 50 day simple moving average is $609.84 and its 200 day simple moving average is $536.74.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.